Immunotherapy may be better than chemotherapy for Merkel cell carcinoma

Immunotherapy May Be Better Than Chemotherapy For Merkel Cell Carcinoma section is one about this Health and Medical Updates categories, published with our scripter Linda Norton just after February 11, 2019, this part probably want to search immediately upon that tags list carcinoma, cell, chemotherapy, immunotherapy, Merkel. I'm blissful to glad you moreover providing that others article related health moreover I am always writting this blogpost routine.

The first study of the immunotherapy drug pembrolizumab as the initial treatment for patients with a rare but aggressive form of skin cancer known as Merkel cell carcinoma reports better responses and longer survival than expected with conventional chemotherapy.

The study, co-led by Suzanne Topalian, M.D., associate director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center, is the longest observation to date of Merkel cell carcinoma patients treated with any anti-PD-1 immunotherapy drug used in the first line. The findings, published in the Journal of Clinical Oncology, supported the recent (Dec. 19, 2018) U.S. Food and Drug Administration accelerated approval of pembrolizumab, marketed as Keytruda, as a first-line treatment for adult and pediatric patients with advanced Merkel cell carcinoma.

For this study, investigators from the Bloomberg~Kimmel Institute collaborated with researchers from the Fred Hutchinson Cancer Research Center in Seattle, along with 11 other U.S. medical centers. The Bloomberg~Kimmel Institute team includes Topalian, William Sharfman, M.D., Evan Lipson, M.D., Abha Soni, D.O., M.P.H., and Janis Taube, M.D., M.Sc.

In the 50-patient study of pembrolizumab as the initial treatment for patients with recurrent, locally advanced or metastatic Merkel cell carcinoma, more than half of the patients (28 patients, 56 percent) had long-lasting responses to the treatment, 12 of whom (24 percent) experienced a complete disappearance of their tumors. Nearly 70 percent of patients in this study were alive two years after starting treatment.

“This is the earliest trial of immunotherapy as a front-line therapy for Merkel cell carcinoma, and it was shown to be more effective than what would be expected from traditional therapies, like chemotherapy,” says Topalian, who is a Bloomberg~Kimmel professor of cancer immunotherapy at the Kimmel Cancer Center. “Immunotherapy provides an effective treatment for patients with Merkel cell carcinoma who before had few options. Immunotherapy is unique in cancer treatment, because it does not directly target cancer cells but rather removes constraints on the immune system’s natural ability to find and destroy cancer cells.”

The 50 patients in this study were treated at 13 centers across the United States in a clinical trial conducted by the Cancer Immunotherapy Trials Network, which is sponsored by the National Cancer Institute (NCI). The Kimmel Cancer Center, where much of the medical science contributing to the development of pembrolizumab unfolded, was a lead institution. Preliminary findings regarding the first 26 patients enrolled in the study were published in the New England Journal of Medicine in 2016. The study was subsequently amended to add 24 more patients.

The National Institutes of Health (NIH) classifies Merkel cell carcinoma as an “orphan disease,” as it is diagnosed in fewer than 2,000 people annually in the United States. It typically occurs in older people and those who have suppressed immune systems. About 80 percent of Merkel cell carcinomas are caused by a virus called the Merkel cell polyomavirus. The remaining cases are attributed to ultraviolet light exposure and other, unknown factors.

In the study, treatment with pembrolizumab worked well against both virus-positive and virus-negative Merkel cell carcinomas, resulting in high response rates and durable progression-free survival in both subtypes. The findings also showed that tumors expressing a PD-1-related protein called PD-L1 tended to respond longer to treatment, although patients whose tumors did not express PD-L1 also responded.

“These findings could be a precursor to developing more effective treatments for other virus-related cancers, which account for about 20 percent of cancers worldwide,” says Sharfman, the Mary Jo Rogers Professor of Cancer Immunology and Melanoma Research.

The non-virus-related subtype is characterized by high numbers of genetic mutations in cancer cells, which has also been shown by the Bloomberg~Kimmel Institute group to be a biomarker of response in various cancers to checkpoint inhibitors such as pembrolizumab.

Pembrolizumab works against Merkel cell carcinoma by blocking PD-1, a molecule on the surface of immune cells that regulates immune responses, turning them on and off. Cancer cells often manipulate PD-1 to send a “stop” signal to the immune system. Blocking that signal with a checkpoint inhibitor, such as pembrolizumab, initiates a “go” signal, sending immune cells to attack cancer cells. A protein on the surface of cancer cells, called PD-L1, is one mechanism cancer cells use to manipulate PD-1 and disrupt the immune response.

“Under the microscope, PD-L1 looks like an armor around the cancer cell,” says Taube, an associate professor of oncology, dermatology and pathology. “Pembrolizumab interrupts PD-1 signaling by blocking the communication between PD-1 and PD-L1, removing…

You might want to go through others chapter health by our related post or you maybe want to checkup much as popular post, I always posting these health article daily for information also clue and trick that one may supporting our health also living the healthy lifestyle. The part is posted just as Linda Norton with the title Immunotherapy May Be Better Than Chemotherapy For Merkel Cell Carcinoma.

Related posts of "Immunotherapy may be better than chemotherapy for Merkel cell carcinoma"

For California attorney general Xavier Becerra, resistance is personal

When President Donald Trump demands a border wall or threatens to deport young unauthorized immigrants, one of the loudest opposition voices comes from the son of Mexican immigrants — who also happens to be California's top lawyer. Democrat Xavier Becerra, the state's first Latino attorney general, is not only one of Trump's biggest critics, he...

MGH researchers identify brain cells that modulate behavioral response to threats

A team of investigators from the Massachusetts General Hospital (MGH) Center for Regenerative Medicine has identified a population of brain cells that appears to play a role in calibrating behavioral responses to potentially threatening situations. In their report published in Nature Neuroscience, the researchers describe finding how activation of a specific group of cells in...

Study examines race-based differences in social support needs among breast cancer patients

Cancer cell during cell division. Credit: National Institutes of Health In a Psycho-Oncology study of 28 women who were being treated for breast cancer and were participating in focus groups, White participants noted that having other breast cancer survivors in their support network was essential for meeting their social support needs. Black participants did not...

Protein widely known to fight tumors also boosts cancer growth

UC San Diego researchers found that the PUMA protein works inside the cell's mitochondria to switch energy production processes and stimulate cancer growth. Credit: Xu Lab, UC San Diego Search for a description of "p53" and it becomes clear that this human protein is widely known for its cancer-fighting benefits, leading to its renown as...

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.